Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Coya Therapeutics, Inc.NASDAQ: COYA
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin widens to 98.9%
Gross margin was 98.9% in Q1 FY2026, up 2020.8 pp from a year earlier. On a trailing-twelve-month basis it was 99.8%, up 378.1 pp year over year.
Context
- Gross margin widened in 1 of the last 2 fiscal years.
- FY2025 was the highest level in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 99.7%
- Year-over-year change
- +333.5pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 99.7% | +333.5pp |
| FY2024 | 2024-12-31 | -233.9% | -242.2pp |
| FY2023 | 2023-12-31 | 8.3% | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Gross Margin vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 gross margin of 99.8% is the highest of the 7 companies compared; the peer median is 35.3%.
- Its year-over-year change of +378.1 pp is the highest of 6, against a peer median of -0.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 99.8% | +378.1 pp | — | |
| LTM Mar 2026 | 99.5% | -0.5 pp | -4.1 pp | |
WHWKWhitehawk Therapeutics Inc | FY2025 | 89.4% | +197.4 pp | +212.8 pp |
| LTM Mar 2026 | 69.9% | +7.9 pp | -24.0 pp | |
| FY2025 | 0.7% | — | -99.4 pp | |
| LTM Mar 2026 | -82.0% | -120.1 pp | +12607.2 pp | |
| LTM Mar 2026 | -182.1% | -260.9 pp | -16.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding COYA) | 35.3% | -0.5 pp | -10.1 pp | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6M | 3.55M | 7.95M |
| Cost of Revenue | 0 | 4.41M | 5.5M | 11.87M | 27.36K |
| Gross Profit | 0 | (4.41M) | 500.68K | (8.31M) | 7.92M |
| Gross Margin | — | — | 8.3% | -233.9% | 99.7% |
| Research & Development | 2.54M | 4.94M | 6.04M | 11.89M | 16.73M |
| Selling, General & Admin | 2.31M | 4.85M | 7.83M | 8.89M | 11.45M |
| Operating Expenses | 4.87M | 5.4M | 8.4M | 8.94M | 28.18M |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| EBITDA | (4.88M) | (9.26M) | (7.33M) | (17.2M) | (21.2M) |
| EBITDA Margin | — | — | -122.2% | -483.9% | -266.8% |
| Operating Income | (4.87M) | (9.81M) | (7.9M) | (17.25M) | (20.27M) |
| Operating Margin | — | — | -131.7% | -485.4% | -255.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (21.48K) | (2.43M) | 639.37K | 1.65M | (957.4K) |
| Income Before Tax | (4.89M) | (12.24M) | (7.26M) | (15.6M) | (21.22M) |
| Pre-Tax Margin | — | — | -121.0% | -439.0% | -267.1% |
| Income Tax Expense | 0 | 0 | 723.85K | (720.29K) | 3.09K |
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Net Margin | — | — | -133.1% | -418.7% | -267.1% |
| EPS (Basic) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| EPS (Diluted) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| Weighted Avg Shares | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
| Weighted Avg Shares (Diluted) | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.